BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8102128)

  • 1. Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins.
    Tecce R; Digiesi G; Savarese A; Trizio D; Natali PG
    Int J Cancer; 1993 Aug; 55(1):122-7. PubMed ID: 8102128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity.
    Di Lazzaro C; Digiesi G; Tecce R; Lotti LV; Torrisi MR; Natali PG
    Cancer Immunol Immunother; 1994 Nov; 39(5):318-24. PubMed ID: 7987863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
    Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
    Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
    Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
    Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented inhibition of tumor cell proliferation in combined use of electroporation with a plant toxin, saporin.
    Mashiba H; Ozaki Y; Matsunaga K
    Ann N Y Acad Sci; 1999; 886():233-5. PubMed ID: 10667227
    [No Abstract]   [Full Text] [Related]  

  • 9. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
    Polito L; Bolognesi A; Tazzari PL; Farini V; Lubelli C; Zinzani PL; Ricci F; Stirpe F
    Leukemia; 2004 Jul; 18(7):1215-22. PubMed ID: 15103391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
    Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
    Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics.
    Natali PG; Nicotra MR; Digiesi G; Cavaliere R; Bigotti A; Trizio D; Segatto O
    Int J Cancer; 1994 Feb; 56(3):341-6. PubMed ID: 7906252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
    Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation.
    Siena S; Bregni M; Formosa A; Martineau D; Lappi DA; Bonadonna G; Gianni AM
    Transplantation; 1988 Nov; 46(5):747-53. PubMed ID: 3264092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
    Flavell DJ; Boehm DA; Noss A; Flavell SU
    Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
    Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
    Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM).
    Barbieri L; Dinota A; Gobbi M; Tazzari PL; Rizzi S; Bontadini A; Lemoli RM; Tura S; Stirpe F
    Eur J Haematol; 1989 Mar; 42(3):238-45. PubMed ID: 2784390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
    Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
    Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6.
    Gasperi-Campani A; Zoli W; Volpi A; Roncuzzi L; Amadori D
    Anticancer Res; 1991; 11(2):1007-11. PubMed ID: 2064307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.